Canaccord raised the firm’s price target on Hinge Health (HNGE) to $63 from $53 and keeps a Buy rating on the shares. The firm saidtThe revenue upside did not match earlier quarter beats, but Hinge’s operating model is humming along as indicated by strong margin performance and a sizable guidance raise. Management alluded to introducing updated long-term operating model targets at its June Movement client conference that includes an investor track.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HNGE:
- Hinge Health Earnings Call Signals Profitable Growth
- Hinge Health Lifts 2026 Outlook After Record Quarter
- Hinge Health Buy Rating Reiterated on Growth Momentum and Migraine Expansion, Price Target Maintained at $72
- Analyst Reiterates Buy on Hinge Health, Citing Near‑Term Outperformance Potential and Long‑Term Growth from New Migraine Care Program
- Hinge Health launching migraine treatment program, WSJ reports